For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of this treatment and Tafamidis meglumine represents a significant breakthrough . These novel therapies protect the transthyretin protein, preventing its damaging build-up and alleviating the impact of the condition . Individuals are now